Serveur Académique Lausannois SERVAL serval.unil.ch

## **Author Manuscript**

**Faculty of Biology and Medicine Publication** 

This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Published in final edited form as:

Title: Advancing synoptic cancer reports beyond English: the University of Bern/PathoLink approach. Authors: Banz Y, Berezowska S, de Leval L, Rubbia-Brandt L, Tolnay M, Moch H, Perren A, Hewer E Journal: Virchows Archiv : an international journal of pathology Year: 2018 Nov Issue: 473 Volume: 5 Pages: 655-656 DOI: 10.1007/s00428-018-2431-0

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.



UNIL | Université de Lausanne Faculty of Biology and Medicine

## Virchows Archiv Advancing synoptic cancer reports beyond English: The University of Bern/PathoLink approach --Manuscript Draft--

Manuscript Number:		
Full Title:	Advancing synoptic cancer reports beyond English: The University of Bern/PathoLink approach	
Article Type:	Letter to the Editor	
Corresponding Author:	Ekkehard Hewer University of Bern Bern, SWITZERLAND	
Corresponding Author Secondary Information:		
Corresponding Author's Institution:	University of Bern	
Corresponding Author's Secondary Institution:		
First Author:	Yara Banz	
First Author Secondary Information:		
Order of Authors:	Yara Banz	
	Sabina Berezowska	
	Laurence de Leval	
	Laura Rubbia-Brandt	
	Markus Tolnay	
	Holger Moch	
	Aurel Perren	
	Ekkehard Hewer	
Order of Authors Secondary Information:		
Funding Information:		
Abstract:	(not applicable)	
Suggested Reviewers:	John Srigley John.Srigley@thp.ca Internationally leading expert on synoptic/structured reporting	
	Familiar with blingual (English/French) health system in Canada	
	Iris Nagtegaal iris.nagtegaal@radboudumc.nl Leading expert on Synoptic/structured reporting	
Opposed Reviewers:		

## Letter to the Editor

Advancing synoptic cancer reports beyond English: The University of Bern/PathoLink approach

Yara Banz<sup>1</sup>, Sabina Berezowska<sup>1</sup>, Laurence de Leval<sup>2</sup>, Laura Rubbia-Brandt<sup>3</sup>, Markus Tolnay<sup>4</sup>, Holger Moch<sup>5</sup>, Aurel Perren<sup>1</sup>, Ekkehard Hewer<sup>1</sup>\*

1: Institute of Pathology, University of Bern, Bern, Switzerland

2: Institute of Pathology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

3: Division of Clinical Pathology, Geneva University Hospital and Faculty of Medicine of Geneva, Geneva, Switzerland

4: Institute for Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland

5: Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland

\*Correspondence to: Ekkehard Hewer, Institute of Pathology, University of Bern, Murtenstrasse 31, 3008 Bern, Switzerland – Telephone: +41 31 632 3211 – <u>ekkehard.hewer@pathology.unibe.ch</u>

Authors' ORCID: YB: 0000-0003-4474-3132; SB: 0000-0001-5442-9791; AP: 0000-0002-6819-6092; EH: 0000-0002-9128-0364

Keywords: Synoptic Reporting; Structured Reporting; Pathology; Medical Terminology; Multilingual Word count: 537

Synoptic reporting (SR) increases completeness and improves the understanding of pathology reports for tumours as compared to the more traditional "narrative" style. Furthermore, it is an important step towards higher levels of structured data capture[4]. SR is defined by a set of required data elements (RDE) specific for each tumour type and a characteristic paired format of RDE and response. The College of American Pathologists (CAP) requires accredited pathology laboratories to report many cancer types in a synoptic format and for this purpose publishes a comprehensive set of protocols[1]. More recently, the International Collaboration for Cancer Reporting (ICCR) – sponsored amongst others by the European Society of Pathology – has started to publish synoptic protocols with the aim to "produce internationally standardised and evidence-based datasets for the pathology reporting of cancer"[2].

One arguably underestimated challenge with regard to widespread implementation of SR is that – with the noteworthy exception of Dutch protocols published by the PALGA foundation[3] – protocols are exclusively available in English. This does not only result in barriers to introduce SR for pathology departments that report in other languages, but also jeopardizes one of the main benefits of SR, i.e. uniformity of terminology between institutions, across country and language barriers. The Institute of Pathology at the University of Bern recently launched an initiative for SR of all major cancer types. Given that the Canton of Bern is bilingual (German and French) and that we report in both languages, we sought to define an approach for translating existing protocols to German as well as French, ensuring precision, clarity and consistency between protocols. Because of the currently much more comprehensive set of protocols, we opted to use CAP (rather than ICCR) protocols, which are freely available (with certain restrictions regarding integration into pathology information systems).

Importantly, we identified recurrent terms and ensured that these were translated consistently between the different protocols (Table 1). We sought to adhere as close as possible to the original English terminology, but found literal translation impracticable for some terms. We made a particular effort to ensure patient safety by avoiding terms prone to misinterpretation. For this purpose, for example, we translated "well differentiated" to German "gut differenziert" rather than the widely used alternative "hoch differenziert" – literally translated: "highly differentiated". This was done to avoid confusion with "hochgradig" ("high grade"). We also made sure that positive and negative responses would not differ by only a single word, the accidental omission of which would invert the meaning. For instance, we translated "not identified" to German "nicht nachgewiesen" rather than the more customary term "nicht vorhanden" for a negative finding, which would differ from "vorhanden" ("present") only by the negation "nicht". Sample reports for the lung carcinoma protocol to highlight these points are provided as supplementary data. Based on our experience with two years of SR, 20 surgical and biomarker protocols adopted so far, and more than 1000 synoptic reports issued, we conclude that widespread implementation of SR in languages other than English is feasible, but neither a trivial nor an effortless endeavour.

All five Swiss academic pathology institutes collaborate to date on PathoLink, a common bilingual (German and French) structured reporting system to enhance data interoperability for cancer registration and data exchange in the frame of personalized health.

Compliance with ethical standards

The authors declare that they have no conflicts of interest.

Authors' contributions: YB, SB, AP and EH contributed to the University of Bern approach to translating and implementing synoptic protocols described herein. LdL, LRB, MT, HM and AP set up the medical and scientific framework of the PathoLink project. EH drafted the manuscript. All authors approved the final version of the manuscript.

English	German	French
Recurrent Terms		
Procedure	Art der Resektion	Type de pièce opératoire
Tumor Site	Tumorlokalisation	Localisation de la tumeur
Histological type	Histologischer Typ	Type histologique
Histological Grade	Histologischer Grad	Grade histologique
Tumor Size, Greatest	Maximaler Tumordurchmesser	Taille de la tumeur, Plus
Dimension		grande dimension
Margin	Resektionsrand	Berge d'exérèse
Treatment Effect	Therapie-Effekt	Réponse au traitement
Regional Lymph Nodes	Regionäre Lymphknoten	Ganglions lymphatiques
		régionaux
Tumor extension	Tumorausdehnung	Extension tumorale
(Lymph Nodes etc.) submitted	Eingesandte (Lymphknoten	(Ganglions etc.) soumis
	etc.)	
(Lymph Nodes etc.) examined	Untersuchte (Lymphknoten	(Ganglions etc.) examinés
	etc.)	, .
(Lymph Nodes etc.) involved	Befallen ( <i>Lymphknoten</i> etc.)	(Ganglions etc.) envahis
Additional Pathologic Findings	Zusätzliche pathologische	Autres lésions
	Befunde	histopathologiques
Mitotic rate	Mitoserate	Index mitotique
Ki-67 labeling index	Prolifererationsrate (Ki-67)	Index de proliferation (Ki-67)
Perineural invasion	Perineuralscheideninfiltration	Infiltration périnerveuse
Not applicable	Nicht zutreffend	Non applicable
Cannot be assessed	Kann nicht beurteilt werden	Ne peut être évalué
Cannot be determined	Kann nicht bestimmt werden	Impossible à déterminer
Recurrent Terms – Special consi		impossible a determiner
Tumor focality	Anzahl Tumorherde	Nombre de foyers tumoraux
Tumor rocality	Literally: "Number of Tumor	Literally: "Number of Tumor
	Foci"	Foci"
Extranodal Extension	Extrakapsuläre Ausbreitung	Effraction capsulaire
	Widely used term	Emaction capsulaire
Brisk / Non-brisk	Reichlich vorhanden ("brisk") /	Intense ("brisk") / modéré
Semiquantitative assessment	spärlich vorhanden ("non-	("non-brisk")
of Tumour-infiltrating	brisk")	
lymophocytes in melanoma	Established English terms in	
	parentheses	
	Tumorfrei	Sain
Uninvolved		
	Literally: "Free of Tumor"	<i>Literally: "Healthy"</i> Bien différencié
Mall differentiated		Bien differencie
Well differentiated	Gut differenziert	
Well differentiated	Rather than "hoch	
Well differentiated	Rather than "hoch differenziert" to avoid	
	Rather than "hoch differenziert" to avoid confusion with "high grade"	
Moderately differentiated	Rather than "hoch differenziert" to avoid confusion with "high grade" Mässig differenziert	Moyennement différencié
Moderately differentiated Poorly differentiated	Rather than "hoch differenziert" to avoid confusion with "high grade" Mässig differenziert Wenig differenziert	Peu différencié
Moderately differentiated Poorly differentiated Present	Rather than "hoch differenziert" to avoid confusion with "high grade" Mässig differenziert Wenig differenziert Vorhanden	Peu différencié Présent
Moderately differentiated Poorly differentiated	Rather than "hoch differenziert" to avoid confusion with "high grade" Mässig differenziert Wenig differenziert Vorhanden Nicht nachgewiesen	Peu différencié
Moderately differentiated Poorly differentiated Present	Rather than "hochdifferenziert" to avoidconfusion with "high grade"Mässig differenziertWenig differenziertVorhandenNicht nachgewiesenRather than "nicht vorhanden"	Peu différencié Présent
Moderately differentiated Poorly differentiated Present	Rather than "hoch differenziert" to avoid confusion with "high grade" Mässig differenziert Wenig differenziert Vorhanden Nicht nachgewiesen	Peu différencié Présent

Table 1: Examples of German and French translations for recurrent terms in the CAP protocols.

Comments in *italics*.

References

- 1. College of American Pathologists. <u>www.cap.org</u>. Accessed 26/06/2018
- 2. International Collaboration for Cancer Reporting. <u>http://www.iccr-cancer.org/</u>. Accessed 26/06/2018
- 3. Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief. <u>www.palga.nl</u>. Accessed 26/06/2018
- 4. Ellis DW, Srigley J (2016) Does standardised structured reporting contribute to quality in diagnostic pathology? The importance of evidence-based datasets Virchows Arch 468:51-59. doi: 10.1007/s00428-015-1834-4

Supplementary Material

Click here to access/download Supplementary Material Synoptic\_Bilingual\_Supplem.docx